Table of Contents Table of Contents
Previous Page  690 / 812 Next Page
Information
Show Menu
Previous Page 690 / 812 Next Page
Page Background

S686

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

3

Parc de Salut Mar, INAD, CSMA, Santa Coloma de Gramanet, Spain

Corresponding author.

Introduction

Extrapyramidal symptoms are well known as side

effects in therapy with antipsychotics. Explore this side effects is

mandatory because they normally are a cause of treatment discon-

tinuation or assess a change in medication. Some studies notice

how long acting injectable antipsychotic cause less extrapyramidal

symptoms than oral treatment, others does not find differences.

Objective

The aim of this study is to analyze the extrapyramidal

symptoms presented on a group of patients treated with aripipra-

zole long acting injectable (ALAI) follow-up in a mental health care

center.

Methods

Descriptive study of a group of patients treated with

ALAI. To assess the possible extrapyramidal symptoms due to treat-

ment we have used the Simpson-Angus Scale (SAS). The follow up

was 3 months after initiation of treatment.

Results

Six patients were included in the study, 2 women (33.3%)

and 4 men (66.7%). The mean age of the sample was 37 years old.

The different diagnoses of the group were 4 patients with psy-

chotic disorder (66.7%; 2 schizophrenia, 1 schizoaffective disorder

and 1 delusional chronic disorder) and the other 2 had an affective

disorder (33.3%; both bipolar disorder). The average score for the

SAS was 1.2 meaning normal results and therefore no significant

extrapyramidal symptoms.

Conclusions

In our sample the average of the results obtained by

applying the SAS is considered within normal limits. In our case as

to extrapyramidal effects ALAI treatment has been well tolerated.

A larger sample would be needed to obtain more reliable results.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2038

EV1054

Neuroleptic prescriptions sequences

analysis in relation to cardiovascular

medication and death occurrence in

Poland

P. Zagozdzon

1 ,

, B. Goyke

2

, P. Dorozynski

3

1

Medical University of Gdansk, Department of Hygiene and

Epidemiology, Gdansk, Poland

2

National Health Fund, Department of Monitoring and Analysis,

Gdansk, Poland

3

Gdansk University of Technology, Faculty of Electronics,

Telecommunications and Informatics, Gdansk, Poland

Corresponding author.

Introduction

The potential role of antipsychotic treatment in

increasing cardiovascular risk and in explaining the increasedmor-

tality due to somatic disorders is still debated. The aim of this study

was to assess the sequences of atypical and atypical neuroleptic

prescriptions in relation to cardiovascular medication and death

occurrence.

Methods

We conducted a retrospective longitudinal analysis

involving 84,881 patients who had drug insurance benefits in

Pomeranian voivodship and who were receiving a typical or atyp-

ical antipsychotic medication between 2008 and 2012. Data on

deaths have been collected from National Death Registry. The

sequence creation was performed according to algorithm that

iterates over neuroleptic prescriptions in chronological order and

appends them to the end of patient’s prescriptions sequence.

Patients were also assigned to cardiovascular groups depending on

the use of cardiovascular or diabetic medications before, simulta-

neously or after the treatment with neuroleptics.

Results

There were 1,095,518 neuroleptic prescriptions and

16,010 deaths among antipsychotic users in analyzed period.

The most prevalent sequence was consisting of typical neurolep-

tics. Less frequent were sequenced with use of both typical and

atypical drugs or only atypical medications. The least frequent were

sequenced with clozapine or clozapine with other neuroleptics.

The highest occurrence of death and occurrence of cardiovascu-

lar drug after introducing antipsychotic treatment was observed

for clozapine. There was lower occurrence of death in atypical neu-

roleptic sequence compared to typical drug sequence but similar

prevalence of cardiovascular drugs.

Conclusion

These results suggest that conventional antipsychotic

medications are associated with increased risk of death compared

to atypical drugs.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2039

EV1055

Indication of depot antipsychotic

treatment in the view of slovak

psychiatrists

M. Zelman

Psychiatricka Nemocnica, Hronovce, Slovakia

With the increasing number of atypical antipsychotics in depot

form, there emerges question about plus and cons of their use in

schizophrenia patients. We focused on the opinion of Slovak psy-

chiatrists about use of this treatment in some specific situations

of schizophrenia treatment. Research was realized via question-

naire on psychiatrists (

n

= 47) from ambulant and hospital care,

during one conference in June 2015. First part of the questionnaire

was focused on the preference of oral or depot form of antipsy-

chotic treatment. Depot form would be indicated by psychiatrists

(in more than 89%) when low compliance, anosognosia or frequent

episodes. On the contrary, oral antipsychotic treatment is preferred

in young patients or employed patients. The type of symptoms (e.g.

positive, negative) has relatively small impact on the preference

of treatment, where the preferences of each type were the lowest

(fewer than 36%). According to the opinion of psychiatrists, depot

antipsychotic treatment is not suitable in first episode of disorder

(according to 81% of respondents), otherwise in second or third

episode it would not be chosen by 6% of asked psychiatrists.

From the aspects of the choice between atypical or typical depot,

atypical antipsychotics in depot formwere favored when presence

of adverse reactions (80%), occurrence of negative symptoms (65%)

and short duration of disorder (58%). Typical depot was preferred

by psychiatrists in patients with chronic states.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2040

EV1056

Asenapine modulates nitric oxide

release and calcium movements in

cardyomyoblasts

P. Zeppegno

, C. Gramaglia , E. Gattoni , S. Gili , E. Gambaro ,

E. Di Tullio , M.C. Rizza , S. Farruggio , L. Camillo , D. Mary ,

G. Vacca , E. Grossini

University of Eastern Piedmont, Traslational Medicine, Novara, Italy

Corresponding author.

Objective

To examine the effects of asenapine on NO release and

Ca

2+

transients in H

9

C

2

, which were either subjected to peroxida-

tion or not.

Materials and methods

H

9

C

2

were treated with asenapine alone

or in presence of intracellular kinases blockers, serotoninergic and

dopaminergic antagonists, and voltage Ca

2+

channels inhibitors.

Experiments were also performed in H

9

C

2

treated with hydrogen

peroxide. NO release and intracellular Ca

2+

weremeasured through

specific probes.